The 3rd Sustainability Report confirms IBSA’s commitment to the well-being of the Person

20 December 2021

BAK publication “The Importance of the Pharmaceutical Industry for Switzerland”

9 December 2021

Helsinn Achieves Carbon Neutrality

6 December 2021

Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron)

2 December 2021

Intervista al Presidente FIT Giorgio Calderari, Falò RSI La 1, giovedì 25 novembre 2021

26 November 2021

BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

19 November 2021

Farma Industria Ticino in Milan for CPhI 2021, 9-11 November 2021

15 November 2021

Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR

12 October 2021

Helsinn Group announces oral presentation of data at AACR-NCI- EORTC relating to a potent and highly selective investigational RET inhibitor

7 October 2021

Site Selection for Life Sciences Companies in Europe – 2021 edition out now

7 October 2021